Zacks Research Weighs in on ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities researchers at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of ResMed in a note issued to investors on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.24 per share for the quarter, up from their prior forecast of $2.19. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.27 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $9.06 EPS, Q2 2026 earnings at $2.32 EPS, Q3 2026 earnings at $2.47 EPS, Q4 2026 earnings at $2.48 EPS, FY2026 earnings at $9.52 EPS and FY2027 earnings at $10.46 EPS.

Other analysts also recently issued research reports about the stock. Bank of America upped their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. KeyCorp increased their target price on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Wolfe Research reissued an “underperform” rating and issued a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. Baird R W raised ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada boosted their target price on shares of ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus price target of $225.70.

ResMed Price Performance

Shares of NYSE RMD opened at $234.77 on Thursday. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $243.03 and its 200 day moving average price is $223.42. ResMed has a 52 week low of $147.39 and a 52 week high of $260.49. The stock has a market cap of $34.46 billion, a price-to-earnings ratio of 30.99, a PEG ratio of 1.71 and a beta of 0.69.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.17. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. ResMed’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.64 earnings per share.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed’s payout ratio is currently 28.08%.

Insider Buying and Selling

In related news, Director Witte Jan De sold 796 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $246.42, for a total value of $246,420.00. Following the sale, the chief financial officer now directly owns 96,812 shares of the company’s stock, valued at approximately $23,856,413.04. This trade represents a 1.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,056 shares of company stock valued at $15,086,020. Insiders own 0.71% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RMD. UMB Bank n.a. grew its stake in ResMed by 1.9% during the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 47 shares during the period. Ascent Group LLC lifted its holdings in shares of ResMed by 1.7% during the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider’s stock valued at $714,000 after acquiring an additional 48 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in ResMed by 3.7% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 52 shares during the period. QRG Capital Management Inc. increased its holdings in ResMed by 4.5% in the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 56 shares in the last quarter. Finally, Inspire Advisors LLC raised its position in ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock valued at $586,000 after purchasing an additional 56 shares during the period. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.